Literature DB >> 32030287

A first attempt to establish a definition of oligometastatic non-small cell lung cancer by a European consensus group.

Koji Haratani1, Masayuki Takeda1, Kazuhiko Nakagawa1.   

Abstract

Entities:  

Year:  2019        PMID： 32030287      PMCID： PMC6988020          DOI： 10.21037/jtd.2019.11.49

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  19 in total

1.  Cancer statistics, 2019.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2019-01-08       Impact factor: 508.702

2.  Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  D Planchard; S Popat; K Kerr; S Novello; E F Smit; C Faivre-Finn; T S Mok; M Reck; P E Van Schil; M D Hellmann; S Peters
Journal:  Ann Oncol       Date:  2018-10-01       Impact factor: 32.976

3.  Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice.

Authors:  Liufu Deng; Hua Liang; Byron Burnette; Michael Beckett; Thomas Darga; Ralph R Weichselbaum; Yang-Xin Fu
Journal:  J Clin Invest       Date:  2014-01-02       Impact factor: 14.808

4.  Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.

Authors:  Martin Reck; Delvys Rodríguez-Abreu; Andrew G Robinson; Rina Hui; Tibor Csőszi; Andrea Fülöp; Maya Gottfried; Nir Peled; Ali Tafreshi; Sinead Cuffe; Mary O'Brien; Suman Rao; Katsuyuki Hotta; Melanie A Leiby; Gregory M Lubiniecki; Yue Shentu; Reshma Rangwala; Julie R Brahmer
Journal:  N Engl J Med       Date:  2016-10-08       Impact factor: 91.245

5.  Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer.

Authors:  Luis Paz-Ares; Alexander Luft; David Vicente; Ali Tafreshi; Mahmut Gümüş; Julien Mazières; Barbara Hermes; Filiz Çay Şenler; Tibor Csőszi; Andrea Fülöp; Jerónimo Rodríguez-Cid; Jonathan Wilson; Shunichi Sugawara; Terufumi Kato; Ki Hyeong Lee; Ying Cheng; Silvia Novello; Balazs Halmos; Xiaodong Li; Gregory M Lubiniecki; Bilal Piperdi; Dariusz M Kowalski
Journal:  N Engl J Med       Date:  2018-09-25       Impact factor: 91.245

Review 6.  Immunogenic cell death and DAMPs in cancer therapy.

Authors:  Dmitri V Krysko; Abhishek D Garg; Agnieszka Kaczmarek; Olga Krysko; Patrizia Agostinis; Peter Vandenabeele
Journal:  Nat Rev Cancer       Date:  2012-11-15       Impact factor: 60.716

7.  Evolution of treatment strategies for oligometastatic NSCLC patients - A systematic review of the literature.

Authors:  Daniel H Schanne; Jana Heitmann; Matthias Guckenberger; Nicolaus H J Andratschke
Journal:  Cancer Treat Rev       Date:  2019-08-28       Impact factor: 12.111

8.  Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non-Small Cell Lung Cancer: Results of the PEMBRO-RT Phase 2 Randomized Clinical Trial.

Authors:  Willemijn S M E Theelen; Heike M U Peulen; Ferry Lalezari; Vincent van der Noort; Jeltje F de Vries; Joachim G J V Aerts; Daphne W Dumoulin; Idris Bahce; Anna-Larissa N Niemeijer; Adrianus J de Langen; Kim Monkhorst; Paul Baas
Journal:  JAMA Oncol       Date:  2019-09-01       Impact factor: 31.777

9.  Pembrolizumab After Completion of Locally Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer: A Phase 2 Trial.

Authors:  Joshua M Bauml; Rosemarie Mick; Christine Ciunci; Charu Aggarwal; Christiana Davis; Tracey Evans; Charuhas Deshpande; Linda Miller; Pooja Patel; Evan Alley; Christina Knepley; Faith Mutale; Roger B Cohen; Corey J Langer
Journal:  JAMA Oncol       Date:  2019-09-01       Impact factor: 31.777

10.  Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer.

Authors:  John Conibear; Brendan Chia; Yenting Ngai; Andrew Tom Bates; Nicholas Counsell; Rushil Patel; David Eaton; Corinne Faivre-Finn; John Fenwick; Martin Forster; Gerard G Hanna; Susan Harden; Philip Mayles; Syed Moinuddin; David Landau
Journal:  BMJ Open       Date:  2018-04-17       Impact factor: 2.692
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.